JP2024102099A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024102099A5 JP2024102099A5 JP2024065367A JP2024065367A JP2024102099A5 JP 2024102099 A5 JP2024102099 A5 JP 2024102099A5 JP 2024065367 A JP2024065367 A JP 2024065367A JP 2024065367 A JP2024065367 A JP 2024065367A JP 2024102099 A5 JP2024102099 A5 JP 2024102099A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- synthetic nanocarrier
- immunosuppressant
- uricase
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002539 nanocarrier Substances 0.000 claims 90
- 239000000203 mixture Substances 0.000 claims 89
- 229960003444 immunosuppressant agent Drugs 0.000 claims 71
- 230000001861 immunosuppressant effect Effects 0.000 claims 71
- 239000003018 immunosuppressive agent Substances 0.000 claims 71
- 108010092464 Urate Oxidase Proteins 0.000 claims 68
- 238000011260 co-administration Methods 0.000 claims 34
- 201000005569 Gout Diseases 0.000 claims 30
- 239000003814 drug Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 229940124597 therapeutic agent Drugs 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- PNFORBBPPMQASU-JTQLQIEISA-N (2s)-2-amino-6-[[4-(2-methoxyethoxy)-4-oxobutanoyl]amino]hexanoic acid Chemical compound COCCOC(=O)CCC(=O)NCCCC[C@H](N)C(O)=O PNFORBBPPMQASU-JTQLQIEISA-N 0.000 claims 14
- 230000002209 hydrophobic effect Effects 0.000 claims 8
- 229920000728 polyester Polymers 0.000 claims 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 6
- 229920001610 polycaprolactone Polymers 0.000 claims 6
- 239000004632 polycaprolactone Substances 0.000 claims 6
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 6
- 229960002930 sirolimus Drugs 0.000 claims 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 6
- 229940116269 uric acid Drugs 0.000 claims 6
- 229940124302 mTOR inhibitor Drugs 0.000 claims 5
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 229960002708 antigout preparations Drugs 0.000 claims 4
- 201000001431 Hyperuricemia Diseases 0.000 claims 3
- 238000009825 accumulation Methods 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical group C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 238000002296 dynamic light scattering Methods 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 claims 1
- 108010068701 Pegloticase Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229960001338 colchicine Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229960001376 pegloticase Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307412P | 2016-03-11 | 2016-03-11 | |
| US62/307,412 | 2016-03-11 | ||
| US201662339944P | 2016-05-22 | 2016-05-22 | |
| US62/339,944 | 2016-05-22 | ||
| US201662346348P | 2016-06-06 | 2016-06-06 | |
| US62/346,348 | 2016-06-06 | ||
| US201662397832P | 2016-09-21 | 2016-09-21 | |
| US62/397,832 | 2016-09-21 | ||
| US201662398422P | 2016-09-22 | 2016-09-22 | |
| US62/398,422 | 2016-09-22 | ||
| US201662403664P | 2016-10-03 | 2016-10-03 | |
| US62/403,664 | 2016-10-03 | ||
| US201662430547P | 2016-12-06 | 2016-12-06 | |
| US62/430,547 | 2016-12-06 | ||
| US201762442948P | 2017-01-05 | 2017-01-05 | |
| US62/442,948 | 2017-01-05 | ||
| JP2018548079A JP7417354B2 (ja) | 2016-03-11 | 2017-03-11 | ペグ化ウリカーゼの処方物および用量 |
| PCT/US2017/021991 WO2017156513A1 (en) | 2016-03-11 | 2017-03-11 | Formulations and doses of pegylated uricase |
| JP2022011177A JP7547402B2 (ja) | 2016-03-11 | 2022-01-27 | ペグ化ウリカーゼの処方物および用量 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022011177A Division JP7547402B2 (ja) | 2016-03-11 | 2022-01-27 | ペグ化ウリカーゼの処方物および用量 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024102099A JP2024102099A (ja) | 2024-07-30 |
| JP2024102099A5 true JP2024102099A5 (https=) | 2025-01-27 |
Family
ID=58464628
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548079A Active JP7417354B2 (ja) | 2016-03-11 | 2017-03-11 | ペグ化ウリカーゼの処方物および用量 |
| JP2022011177A Active JP7547402B2 (ja) | 2016-03-11 | 2022-01-27 | ペグ化ウリカーゼの処方物および用量 |
| JP2024065367A Pending JP2024102099A (ja) | 2016-03-11 | 2024-04-15 | ペグ化ウリカーゼの処方物および用量 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548079A Active JP7417354B2 (ja) | 2016-03-11 | 2017-03-11 | ペグ化ウリカーゼの処方物および用量 |
| JP2022011177A Active JP7547402B2 (ja) | 2016-03-11 | 2022-01-27 | ペグ化ウリカーゼの処方物および用量 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20170258927A1 (https=) |
| EP (2) | EP4445955A3 (https=) |
| JP (3) | JP7417354B2 (https=) |
| KR (3) | KR20180120753A (https=) |
| CN (1) | CN109152819A (https=) |
| AU (2) | AU2017230891B2 (https=) |
| BR (1) | BR112018068249A2 (https=) |
| CA (1) | CA3017365A1 (https=) |
| DK (1) | DK3426285T3 (https=) |
| ES (1) | ES2986077T3 (https=) |
| FI (1) | FI3426285T3 (https=) |
| HR (1) | HRP20241127T1 (https=) |
| HU (1) | HUE068144T2 (https=) |
| IL (2) | IL318183A (https=) |
| LT (1) | LT3426285T (https=) |
| MX (1) | MX2018011012A (https=) |
| PL (1) | PL3426285T3 (https=) |
| PT (1) | PT3426285T (https=) |
| RS (1) | RS65941B1 (https=) |
| SI (1) | SI3426285T1 (https=) |
| WO (1) | WO2017156513A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG161247A1 (en) | 2005-04-11 | 2010-05-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
| US9377454B2 (en) | 2009-06-25 | 2016-06-28 | Crealta Pharmaceuticals Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
| MX374963B (es) | 2011-04-29 | 2025-03-06 | Selecta Biosciences Inc | Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos. |
| KR20140050698A (ko) | 2011-07-29 | 2014-04-29 | 셀렉타 바이오사이언시즈, 인크. | 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체 |
| BR122020023215B1 (pt) | 2013-05-03 | 2022-11-22 | Selecta Biosciences, Inc | Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico |
| JP7242180B2 (ja) | 2014-09-07 | 2023-03-20 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物 |
| KR20180120753A (ko) * | 2016-03-11 | 2018-11-06 | 셀렉타 바이오사이언시즈, 인크. | Peg화 우리카제의 제제 및 용량 |
| CN116637177A (zh) | 2016-11-11 | 2023-08-25 | 好利恩治疗美国公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| ES3036482T3 (en) | 2017-03-11 | 2025-09-19 | Cartesian Therapeutics Inc | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| AU2018297309A1 (en) | 2017-07-07 | 2020-01-30 | Allena Pharmaceuticals, Inc. | Recombinant uricase enzyme |
| CN109875988B (zh) * | 2018-09-13 | 2021-08-27 | 江西中医药大学 | 一种化合物dhnb缩氨基脲的合成及其在防治痛风与高尿酸血症的应用 |
| WO2020160322A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple) |
| WO2020160325A1 (en) | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| AU2020287627A1 (en) | 2019-06-04 | 2021-11-18 | Selecta Biosciences, Inc. | Formulations and doses of PEGylated uricase |
| KR102260478B1 (ko) * | 2019-08-19 | 2021-06-02 | 연세대학교 산학협력단 | 일나트륨 요소화물 결정 용해용 조성물 |
| EP4021482A4 (en) * | 2019-08-30 | 2023-04-19 | Horizon Therapeutics Ireland Dac | PEGLOTICASE FOR THE TREATMENT OF GOUT IN KIDNEY TRANSPLANT RECIPIENT |
| EP4048269A1 (en) * | 2019-10-21 | 2022-08-31 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
| CN118384281A (zh) * | 2019-11-08 | 2024-07-26 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
| KR102200329B1 (ko) * | 2019-11-11 | 2021-01-08 | 광주과학기술원 | 반감기 증가를 위한 치료용 단백질-지방산 접합체 및 이의 용도 |
| EP4588513A3 (en) * | 2020-08-10 | 2025-10-22 | Horizon Therapeutics USA, Inc. | Methods of treating gout |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
| WO2025076412A1 (en) * | 2023-10-04 | 2025-04-10 | Gro Biosciences Inc. | Modified polypeptides and methods of making and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
| US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
| US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
| JP3462313B2 (ja) | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法 |
| US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
| AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
| JP4751556B2 (ja) | 2000-02-28 | 2011-08-17 | ジーンシーグス， インコーポレイテッド | ナノカプセルカプセル化システムおよび方法 |
| GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
| US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| WO2003020797A1 (en) | 2001-08-30 | 2003-03-13 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| MXPA06006738A (es) | 2003-12-19 | 2006-08-31 | Univ North Carolina | Metodos para fabricar micro- y nano-estructuras aisladas utilizando litografia suave o de impresion. |
| WO2006080951A2 (en) | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
| JP2011500569A (ja) | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
| CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| MX374963B (es) * | 2011-04-29 | 2025-03-06 | Selecta Biosciences Inc | Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos. |
| BR122020023215B1 (pt) * | 2013-05-03 | 2022-11-22 | Selecta Biosciences, Inc | Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico |
| AU2014262164B2 (en) * | 2013-05-03 | 2020-02-27 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
| KR102601922B1 (ko) | 2014-11-05 | 2023-11-15 | 셀렉타 바이오사이언시즈, 인크. | 안정한 과-포화 상태로 라파마이신을 포함하는 합성 나노담체와 관련된 방법 및 조성물 |
| KR20180120753A (ko) * | 2016-03-11 | 2018-11-06 | 셀렉타 바이오사이언시즈, 인크. | Peg화 우리카제의 제제 및 용량 |
-
2017
- 2017-03-11 KR KR1020187029146A patent/KR20180120753A/ko not_active Ceased
- 2017-03-11 PL PL17715298.0T patent/PL3426285T3/pl unknown
- 2017-03-11 KR KR1020267002811A patent/KR20260023090A/ko active Pending
- 2017-03-11 PT PT177152980T patent/PT3426285T/pt unknown
- 2017-03-11 RS RS20240946A patent/RS65941B1/sr unknown
- 2017-03-11 EP EP24177803.4A patent/EP4445955A3/en active Pending
- 2017-03-11 US US15/456,520 patent/US20170258927A1/en not_active Abandoned
- 2017-03-11 WO PCT/US2017/021991 patent/WO2017156513A1/en not_active Ceased
- 2017-03-11 ES ES17715298T patent/ES2986077T3/es active Active
- 2017-03-11 KR KR1020227029367A patent/KR102921105B1/ko active Active
- 2017-03-11 IL IL318183A patent/IL318183A/en unknown
- 2017-03-11 CA CA3017365A patent/CA3017365A1/en active Pending
- 2017-03-11 SI SI201731543T patent/SI3426285T1/sl unknown
- 2017-03-11 AU AU2017230891A patent/AU2017230891B2/en active Active
- 2017-03-11 HR HRP20241127TT patent/HRP20241127T1/hr unknown
- 2017-03-11 FI FIEP17715298.0T patent/FI3426285T3/fi active
- 2017-03-11 HU HUE17715298A patent/HUE068144T2/hu unknown
- 2017-03-11 DK DK17715298.0T patent/DK3426285T3/da active
- 2017-03-11 LT LTEPPCT/US2017/021991T patent/LT3426285T/lt unknown
- 2017-03-11 BR BR112018068249-7A patent/BR112018068249A2/pt unknown
- 2017-03-11 JP JP2018548079A patent/JP7417354B2/ja active Active
- 2017-03-11 EP EP17715298.0A patent/EP3426285B1/en active Active
- 2017-03-11 CN CN201780028609.1A patent/CN109152819A/zh active Pending
- 2017-03-11 MX MX2018011012A patent/MX2018011012A/es unknown
-
2018
- 2018-09-12 IL IL261700A patent/IL261700A/en unknown
-
2022
- 2022-01-27 JP JP2022011177A patent/JP7547402B2/ja active Active
-
2024
- 2024-04-15 JP JP2024065367A patent/JP2024102099A/ja active Pending
- 2024-07-15 AU AU2024204851A patent/AU2024204851A1/en not_active Abandoned
- 2024-08-29 US US18/818,714 patent/US20250090451A1/en active Pending
- 2024-10-31 US US18/933,195 patent/US20250057756A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024102099A5 (https=) | ||
| JP2022068180A5 (https=) | ||
| JP2019507797A5 (https=) | ||
| US12303478B2 (en) | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state | |
| FI3426285T3 (fi) | Pegyloidun urikaasin formulaatioita ja annoksia | |
| KR20150040338A (ko) | 다발경화증 치료용 조합 요법 | |
| JP2020510687A5 (https=) | ||
| US11903908B2 (en) | Methods of administering amantadine | |
| US11607389B2 (en) | Delayed release deferiprone tablets and methods of using the same | |
| JP2023501457A5 (https=) | ||
| IL305412A (en) | Methods for treating disorders ameliorated by muscarinic receptor activation | |
| EP4122445A1 (en) | Dosage form for intra-articular injection comprising colchicine for use in the treatment of crystal-and non-crystal associated acute inflammatory arthritis | |
| US20250144057A1 (en) | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state | |
| AU2020235442A1 (en) | Capsid assembly modulator solid formulation | |
| JP6697539B2 (ja) | コルヒチンの徐放性製剤およびその使用方法 | |
| BR122025009427A2 (pt) | Composições de gama-hidroxibutirato, usos de gama-hidroxibutirato e métodos de preparação das composições e micropartículas de liberação modificada ou imediata de oxibato de sódio |